Search Results

You are looking at 1 - 1 of 1 items for

  • Author: Yvonne A. Efebera x
Clear All Modify Search
Full access

Yvonne A. Efebera and Nina Shah

The number of approved regimens for multiple myeloma has increased dramatically in recent years, improving progression-free and overall survival while also increasing the complexity of treatment decisions. Despite the plethora of options available, one fundamental treatment question remains: How long should initial therapy last? At the NCCN 2019 Annual Congress: Hematologic Malignancies, Drs. Yvonne A. Efebera and Nina Shah debated whether myeloma therapy should be time-limited or continue until disease progression.